Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease
NARecruitingINTERVENTIONAL
Enrollment
106
Participants
Timeline
Start Date
October 31, 2024
Primary Completion Date
April 30, 2028
Study Completion Date
April 30, 2028
Conditions
Cerebral Small Vessel Disease
Interventions
DRUG
XBD173
4 weeks treatment
Trial Locations (1)
Unknown
RECRUITING
Imperial Clinical Research Facility, London
All Listed Sponsors
lead
Imperial College London
OTHER
NCT06643013 - Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease | Biotech Hunter | Biotech Hunter